The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in treatment of uncomplicated lower urinary tract infections.

2024-518988-35-00 Protocol SPh/01/2024 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 1 Apr 2025 · End 28 May 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol SPh/01/2024

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 34
Countries 1
Sites 1

Not applicable (submitted trial is a bioequivalence in healthy subjects)

Key facts

Sponsor
Sciencepharma Sp. z o.o.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Bacterial Infections and Mycoses [C01]
Trial duration
1 Apr 2025 → 28 May 2025
Decision date (initial)
2025-03-31
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Not applicable (submitted trial is a bioequivalence in healthy subjects)

VersionLevelCodeTermSystem organ class
24.0 LLT 10085331 Lower urinary tract infection bacterial 100000004848

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Sciencepharma Sp. z o.o.

Sponsor organisation
Sciencepharma Sp. z o.o.
Address
Ul. Chelmska 30/34
City
Warsaw
Postcode
00-725
Country
Poland

Scientific contact point

Organisation
Sciencepharma Sp. z o.o.
Contact name
Clinical Trials Team

Public contact point

Organisation
Sciencepharma Sp. z o.o.
Contact name
Clinical Trials Team

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 34 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Quinta-Analytica s.r.o.
Quinta-Analytica, Prazska 1486/18c, Hostivar, Prague

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2025-04-01 2025-05-28 2025-04-14 2025-04-26

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-02-20 Czechia Acceptable
2025-03-25
2025-03-31